A Phase 2, Double-blind Dose Escalation Regimen of Once-Weekly OPK-88003 in Subjects With Type 2 Diabetes

Trial Profile

A Phase 2, Double-blind Dose Escalation Regimen of Once-Weekly OPK-88003 in Subjects With Type 2 Diabetes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Pegapamodutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors OPKO Health
  • Most Recent Events

    • 23 Mar 2018 According to the OPKO Health media release, first patient has been enrolled in this study.
    • 23 Mar 2018 Status changed from not yet recruiting to recruiting, according to the OPKO Health media release.
    • 16 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top